诱导多能干细胞
心脏毒性
再生医学
神经科学
医学
疾病
药物发现
心肌细胞
干细胞
转化医学
个性化医疗
生物信息学
药理学
生物
胚胎干细胞
内科学
病理
细胞生物学
化疗
基因
生物化学
作者
Michelangelo Paci,Kirsi Penttinen,Mari Pekkanen-Mattila,Jussi T. Koivumäki
出处
期刊:Journal of Cardiovascular Pharmacology
[Ovid Technologies (Wolters Kluwer)]
日期:2020-12-15
卷期号:77 (3): 300-316
被引量:7
标识
DOI:10.1097/fjc.0000000000000972
摘要
Abstract: Despite major efforts by clinicians and researchers, cardiac arrhythmia remains a leading cause of morbidity and mortality in the world. Experimental work has relied on combining high-throughput strategies with standard molecular and electrophysiological studies, which are, to a great extent, based on the use of animal models. Because this poses major challenges for translation, the progress in the development of novel antiarrhythmic agents and clinical care has been mostly disappointing. Recently, the advent of human induced pluripotent stem cell–derived cardiomyocytes has opened new avenues for both basic cardiac research and drug discovery; now, there is an unlimited source of cardiomyocytes of human origin, both from healthy individuals and patients with cardiac diseases. Understanding arrhythmic mechanisms is one of the main use cases of human induced pluripotent stem cell–derived cardiomyocytes, in addition to pharmacological cardiotoxicity and efficacy testing, in vitro disease modeling, developing patient-specific models and personalized drugs, and regenerative medicine. Here, we review the advances that the human induced pluripotent stem cell–derived-based modeling systems have brought so far regarding the understanding of both arrhythmogenic triggers and substrates, while also briefly speculating about the possibilities in the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI